MarketResearch.biz delivers in-depth insights on the global dry powder inhaler market in its upcoming report titled, “Global Dry Powder Inhaler Market Trends, Applications, Analysis, Growth, and Forecast: 2018 to 2027”. The global dry powder inhaler market is estimated to register a CAGR of X.X% in terms of value during forecast period 2018–2027. The report offers in-depth insights, revenue details, and other vital information regarding the target market, and the various trends, drivers, restraints, opportunities, and threats till 2027. The report offers insightful and detailed information regarding the various key players operating in the market, their financials, supply chain trends, technological innovations, key developments, apart from future strategies, acquisitions & mergers, and market footprint. The global dry powder inhaler market report has been segmented on the basis of product type, distribution channel, application, and region.
Dry powder inhaler (DPI) is a device used to deliver medication to lungs in the form of powder. Dry powder inhaler is used to treat respiratory diseases such as asthma, bronchitis, emphysema, etc. DPI are better alternatives to conventional inhalers such as metered-dose inhalers. The dry powder inhaler is breath activated, where the drug or medicine is released to lungs only after taking a fast deep breath through inhaler.
Increasing incidence of respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), chronic bronchitis, etc. across the globe is a major factor driving growth of the global dry powder inhaler market. In addition, demand for cost effective devices for treatment of respiratory disorders among the users is another factor expected to support growth of target market.
However, high cost of device is a major factor restraining growth of the global dry powder inhaler market. In addition, stringent government regulations related to device approval is other factor expected to restrain growth of the global dry powder inhaler market.
Advancements such as development of dry powder inhaler that provides high dose and systemic delivery of medications into lungs, is expected to create potential revenue opportunities to players operating in the global dry powder inhaler market.
North America market is expected to account for highest share in the global market in terms of revenue, owing to increasing incidences of chronic respiratory diseases such as asthma, bronchitis, and many more. In addition, significant presence of prominent players operating in the market in this region is another factor contributing to growth in North America. Europe market is projected to account for second-largest revenue share in the global market, followed by markets in Asia Pacific, Latin America, and Middle East & Africa respectively. The market in Asia Pacific is projected to witness highest CAGR in terms of revenue over the forecast period. This can be attributed to rising demand for cost effective respiratory devices. Additionally, rising disposable income, increasing investments for development of healthcare sector in emerging economies such as China, Japan, and India is expected to further impel growth of the Asia Pacific market in the near future.
Global Dry Powder Inhaler Market is segmented into:
By Product Type:
- Single Dose Dry Powder Inhaler
- Multiple Dose Dry Powder Inhaler
By Distribution Channel:
- Retail Pharmacies
- Drug Stores
- Chronic Obstructive Pulmonary Disease
- Pulmonary Arterial Hypertension
- North America
- Asia Pacific
- Latin America
- Middle East & Africa
Attribute Report Details Market Size Ask For Market Size Growth Rate Ask For Growth Rate Key Companies Ask For Companies Report Coverage Revenue analysis, Competitive landscape, Key company analysis, Market Trends, Key segments, Distribution Channel, Market Dynamics, COVID-19 Impact Analysis and more… Historical Data Period 2015-2020 Base Year 2022 Forecast Period 2022-2031 Region Scope North America, Europe, Asia-Pacific, South America, Middle East & Africa Country Scope United States, Canada and Mexico, Germany, France, UK, Russia and Italy, China, Japan, Korea, India and Southeast Asia, Brazil, Argentina, Colombia etc.Saudi Arabia, UAE, Egypt, Nigeria and South Africa Revenue in US$ Mn
- AstraZeneca PLC
- GlaxoSmithKline plc
- Vectura Group plc
- Boehringer Ingelheim GmbH
- Otsuka Pharmaceutical Co. Ltd.
- Norton Healthcare, Inc.
- Respira Therapeutics, Inc.
- Cipla Inc.
- Teicos Pharma Ltd.
- Luckys Pharma
Request for TOC
Why Choose Us
- 360 Degree Approach
- Growth Consulting
- 24/7 Research Support
- Comprehensive-Level of Customization
- Comprehensive-Level of Customization
- Competitive Intelligence
- Single-Country/ Region Intelligence
- Post-Sale Service Assistance
- Access to Lead Analysts
- Available in PDF, Excel, Word/ PPT
Request for Customization
Don't just take our word. We are trusted by these great companies!